Background: The reversibility of pulmonary arterial hypertension (PAH) in congeni-
| INTRODUCTION
Pulmonary arterial hypertension (PAH), characterized by increased pulmonary arterial pressure (PAP), pulmonary vascular resistance (PVR) and aggravated right heart function, is a common combination of congenital heart disease (CHD). Long-time exposure to high blood flow in CHD patients can lead to endothelial dysfunction and pulmonary vascular remodelling, which may finally result in irreversible pulmonary vasculopathy. Studies showed prevalence from 4% to 28%, 1,2 and 30% of unrepaired CHD patients have PAH. 3 Our previous data showed that 47.5% of Chinese CHD patients complicated by PAH. 4 Interventional and surgical repair as the main treatment for CHD has proved to be highly beneficial for the patients. But a study
showed that 14% of patients were affected with PAH after the correction of complete atrioventricular septal defects, and the 1-year mortality of CHD-PAH patients who underwent cardiac operations reached 18.5%. 3 Studies even showed a worse 10-year postoperative survival for patients with persistent post-operative PAH than for those with Eisenmenger syndrome, 5, 6 which was considered the severe and irreversible condition of CHD-PAH. It means that the pulmonary vascular lesion had become irreversible and the abnormality in haemodynamics cannot be reversed by surgical repair in these patients. Furthermore, the condition may be even worse because of the sudden haemodynamics change after surgery. Despite advances in our understanding of the pathophysiology and the management of PAH, significant translational and therapeutic gaps remained for the medication. 7 That raised the importance of accurate evaluation and gaining a better understanding about the reversibility of PAH in CHD patients before surgery. As of now little is known about that.
To explore the pathogenetic mechanism of irreversible CHD-PAH, proteomics comparison of the lung tissues in both reversible and irreversible CHD-PAH patients as well as in normal were performed. Proteomic analysis showed that transgelin was significantly up-regulated (2.5-fold) in irreversible CHD-PAH group compared to the reversible and control group. 8 Immunohistochemical staining and
Western blot also confirmed the findings, and the expression of transgelin was significantly positively related with pathological grading of pulmonary arterioles. It indicated that transgelin may be an important potential target for the development of irreversible pulmonary vascular lesion in CHD patients.
Transgelin, a 22-kD protein of the calponin family which is also known as SM22α,WS3-10 or p27, is exclusively and abundantly expressed in the cytoskeleton of visceral and vascular smooth muscle cells of adult animals. It is also the earliest markers of smooth muscle differentiation. Studies have elucidated the regulating functions of transgelin, including actin cytoskeleton rearrangement, phenotypic modulation of vascular smooth muscle cells (SMC), SMC proliferation, cell migration and tumour suppression. [9] [10] [11] [12] It is unknown how transgelin influence the PAH development in CHD. In immunohistochemical staining of the lung tissue, transgelin was obviously expressed in pulmonary arterial smooth muscle cells (PASMC)
of the remodelled and thickened pulmonary arterioles, especially in irreversible CHD-PAH group. We speculated that transgelin may influence the PASMC function and then promote the pulmonary vascular remodelling and irreversible CHD-PAH occurrence.
Based on the research findings on lung tissue samples, further cellular experiment was carried out to illuminate the role of transgelin in regulating the function of PASMC. We demonstrated that knockdown and overexpression of transgelin can affect the PASMC phenotype, proliferation, apoptosis and migration.
| METHODS

| Patient enrolment and lung biopsy
According to multidisciplinary and translational approaches guideline, 13 14 CHD-PAH patients diagnosed by right heart catheterization (RHC) who met the inclusion criteria and would undergo complete repair surgery were prospectively enrolled. Lung biopsy was performed during the repair surgery with patients' informed consent. The control normal lung tissues were from patients who would undergo surgery for bronchial carcinoma (n = 6). 
| Qualitative and quantitative analysis of the expression of transgelin in the lung tissue of each group
In MS analysis, transgelin expression was significantly increased in the lung tissue of CHD-PAH patients, and its expression level in irreversible group was 2.5-fold than that of the reversible group.
To confirm the proteomic findings of transgelin, immunohistochemical staining and Western blot were performed for qualitative and quantitative analysis of the expression of transgelin in the lung tissue of CHD-PAH patients and normal lung tissue.
| Immunohistochemical staining
Neutral formalin-fixed lung tissues were made into 4-5 μm sections after dehydration and paraffin embedding. After heating for antigen retrieval, 3% H 2 O 2 was used to block endogenous peroxidase.
The sections were incubated with transgelin (SM22α) antibody (Abcam corporation) at 4°C overnight. After incubation of second antibody for 30 minutes at room temperature and DAB colouration, the slides were covered with resin, and then observed under microscope. 
| Western blot
| Lentiviral infection
Lentivirus/GV248-siTAGLN (hU6-MCS-Ubiquitin-EGFP-IRES-puromycin) and lentivirus/GV358 -TAGLN (Ubi-MCS-3FLAG-SV40-EGFP-IRES-puromycin) and their corresponding control lentiviruses, lentivirus/GV248 and lentivirus/GV358 respectively, were obtained from were seeded in a six-well plate. After cell culture for 24 hours, the medium was replaced by 0. 
| Quantitative real-time polymerase chain reaction (RT-PCR)
Total RNA from the cultured cells of each group was extracted using TRIZOL (Invitrogen, USA). Quantification was performed with a twostep reaction process: reverse transcription (RT) and PCR. The RNA was reversely transcribed to cDNA using the PrimeScript ™ RT Master Mix kit (TaKaRa, Japan). PCR was performed on the 7500 realtime PCR system (Applied Biosystems, USA) using Power SYBR to ACTB and were calculated using the 2 −ΔΔCt method.
| Cell protein expression in Western blot
Proteins of the cultured cells of each group were extracted with RIPA lysis buffer. The process of electrophoresis, transfer membrane, antibody incubation and imaging was as described above. 
| Cell proliferation assay
Cell count and EdU staining assay were used to evaluate the cell proliferation after transfection. The cells were washed with PBS gentlely for two times to clear the residual medium. After detaching by 0.25% trypsin-EDTA, the cells were resuspended in 1 ml DMEM.
Number of the cells in each group was manually counted using a haemocytometer. Cell proliferation after treatment was also observed under microscope.
| EdU staining assay
Cells were cultured on the coverslips. Cell proliferation of the each group was determined using the Click-iT ® EdU Alexa Fluor Proliferation was presented as % proliferative cells. The assay was repeated for at least three times to achieve statistical analysis.
| Cell apoptosis assay
Cell apoptosis was determined by terminal deoxyribonucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay and Annexin-V flow cytometry.
| TUNEL assay
Cells were cultured on the coverslips. Apoptosis of the treated cells were detected using one-step TUNEL cell apoptosis detection kit and control group. The assay was repeated for at least three times to achieve statistical analysis.
| Annexin-V flow cytometry
The cell apoptosis was detected using Annexin V/APC-7ADD apoptosis detection kit (KeyGEN BioTECH, China) according to the manufacturer's instructions in the meanwhile. Treated cells were harvested and washed twice with ice-cold phosphate buffer solution.
Then the cells were resuspended in 500 ul binding buffer, incubated with 5 ul Annexin V-APC and 5 ul 7-amino-actinomucin D (7-ADD) for 15 minutes. All the samples were immediately analysed using a flow cytometer (Accuri C6, BD Biosciences, USA). The assay was repeated for at least three times to achieve statistical analysis.
| Transwell migration assays
After transfection for 84 hours, cells were starved with DMEM 
| Statistical analysis
Statistical analysis was performed with SPSS 
| Transgelin influences proliferation of hPASMC
Cell count analysis presented that the number of living cells was much less in LV-siTAGLN group while significantly more in 
| Transgelin influence apoptosis of hPASMC
The results of TUNEL assay ( Figure 7 ) and Annexin-V flow cytometry ( Figure 8 ) showed a significant increase in hPASMC apoptosis ratio in LV-siTAGLN group (P < 0.05), while the apoptosis ratio was similar in LV-TAGLN group and its control group. In WB ( Figure 3B 
| Transgelin influenced migration of hPASMC
Transwell migration assays showed a distinct effect of transgelin on the migration of hPASMC, as it shown in Figure 9 . HPASMC migra- 
| Transgelin and CHD-PAH development
Studies indicated that the severity of pulmonary vasculature remodelling adversely influenced the natural history and operative mortality in CHD-PAH patients. [14] [15] [16] But the mechanism of pulmonary remodelling is poorly understood in irreversible CHD-PAH.
Transgelin as an important cytoskeletal protein has been demon- 
| Transgelin and PASMC proliferation, migration, apoptosis and phenotype
In studies, transgelin was demonstrated with a divergent function on cell proliferation, migration and apoptosis under different conditions.
Daniel's study demonstrated that transgelin was up-regulated in repopulating mesangial cells and promoted their migratory and proliferative nature after injury. 18 It was reported in another study that increased alveolar epithelial type II cell expression of transgelin contributed to cell migration in lung fibrosis through TGF-β/Smad3 pathway. 19 In contrast, study also found that overexpression of transgelin inhibited VSMC proliferation and neointima formation via blockade of the Ras-extracellular signal-regulated kinase (ERK) 1/2 pathway. 20 Transgelin even presented different regulating effects of migration on VSMC under different cell phenotype. 21 Transgelin which was considered as a tumour suppressor was shown to suppress proliferation of HepG2 cells, while the transgelin -overexpressing cells became resistant to apoptotic cell death caused by cytotoxic agents. 22 In the present study, transgelin overexpression activated PASMC proliferation and migration distinctly, and meanwhile the PASMC was likely anti-apoptotic as the anti-apoptotic protein (bcl-2) was sig- 29 However, the molecular mechanism of phenotypic transition presented unknown, the reorganization of the actin cytoskeleton seemed to be involved in that process. [30] [31] [32] In this in vitro experiment, transgelin seemed to regulate the Study have reported an up-regulation of RAGE in pulmonary arterioles of PAH patients, as well as experimental PAH models.
Receptor for advanced glycation end-products (RAGE) activation promoted PASMC proliferation and resistance to apoptosis. This raised doubts on the important role of RAGE on PAH development. 39 Studies in vitro reported that RAGE activation decreased the expression of transgelin on both mRNA and protein levels, and interfered with the contractile phenotype of VSMC, 40 and RAGE activation-induced apoptosis in VSMC. 41 We may also consider RAGE as an important upstream regulating factor of transgelin in CHD-PAH although the increased RAGE repression did not reach a significant level in our previous proteomics analysis.
However, the expression of transgelin in our study of CHD-PAH was significantly up-regulated, and the increased transgelin promoted PASMC proliferation and resistance to apoptosis. The regulatory mechanism of RAGE and transgelin seemed to be complicated and we suspect that some other signals may also be involved in.
Proteomics analysis of our previous work also showed obvious activation of adhesion-integrin-mediated cell adhesion and migration. FAK, which is activated by growth factor receptors and integrin clustering is required for cell adhesion, migration and other aspects of the remodelling process. FAK activation was closely related with VSMC proliferation, migration and phenotypes. 42, 43 FRNK, a specific FAK inhibitor, was selectively expressed in large arterioles when SMC are transitioning from a synthetic to contractile phenotype, and inhibited FAK-dependent SMC proliferation and migration. FAK activation significantly reduced SM22 (transgelin) and α-SMA expression, 42 leading to cell proliferation and modulation from a contractile phenotype to a synthetic phenotype. 44 Studies also showed that FAK activation requires signalling by both the growth factor receptors and the fibronectin-binding integrin. 44 TGF-β could induce FRNK expression and then restrained FAK activation, which finally stimulated SM marker gene expression. 42 These results may remind us that FAK is an upstream regulating factor of transgelin, and the abnormal expres- 
| LIMITATION
We also have some limitations in this study. First, we lack the animal experimental research to test and verify the role of transgelin in the development of CHD-PAH and irreversible pulmonary vasculopathy.
Second, we failed to explore the upstream mechanism of the increased expression of transgelin in the pulmonary arterioles of CHD-PAH patients under the present research conditions on lung tissue and in vitro cell lines. Our future research work will explore these discrepancies.
| CONCLUSION S
We conclude that transgelin is a potential important target in the 
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